Numbers for Stage 2 meaningful use attestation remain very low, according to the latest numbers from the Centers for Medicare and Medicaid Services.
Numbers for Stage 2 meaningful use attestation remain very low, according to the latest numbers from the Centers for Medicare and Medicaid Services (CMS).
During a Sept. 3 Health IT Policy Committee meeting, CMS reported 143 eligible hospitals and 3,125 eligible professionals attested to Stage 2 meaningful use as of August 25. Although these numbers represent an 83% and 66% increase, respectively, since August 1, they are still sluggish, according to Health Data Management.
The College of Healthcare Information Management Executives (CHIME) estimated that roughly 50% of eligible hospitals and critical access hospitals are scheduled to meet Stage 2 requirements this year, and nearly 85% will be need to meet requirements in 2015.
Although CMS released on August 29 a new final rule that allows more flexibility in how providers use certified electronic health record (EHR) technology (CEHRT) to meet meaningful use requirements in 2014, CHIME president and chief executive officer Russell P. Branzell, FCHIME, CHCIO, expressed his dismay with the modification.
While providers can use either the 2011 Edition CEHRT or a combination of 2011 and 2014 Edition CEHRT when reporting in 2014, they are still required to use the 2014 CEHRT Edition in 2015.
“Most hospitals who take advantage of new pathways made possible through this final rule will not be in a position to meet Stage 2 requirements beginning October 1, 2014,” Branzell said in a statement. “This means that penalties avoided in 2014 will come in 2015, and millions of dollars will be lost due to misguided government timelines.”
Furthermore, CHIME believed the final rule’s requirement of 365 days of EHR reporting in 2015 ensures that the industry’s struggles with EHR adoption and meaningful use participation will continue.
Instead, CHIME recommends offering providers the option in 2015 of reporting any 3-month quarter EHR reporting period.
“This sensible recommendation, if taken, would have assuaged industry concerns over the pace and trajectory of rulemaking; it would have pushed providers to meet a higher bar, without pushing them off the cliff; and it would have ensured the long-term vitality of the program itself,” Branzell said.
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Federated Learning Models Show Potential in Melanoma-Nevus Classification, but Improvements Needed
March 16th 2024A multicentric, single-arm diagnostic study created a decentralized federated learning model for the classification of invasive melanomas and nevi, showcasing comparable results to centralized data models.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen